Kidney function is frequently impaired in patients with cancer due to preexisting chronic kidney disease, cancer-associated factors, and prior anticancer treatments. Given these multifactorial insults, accurate assessment of kidney function is critical to determining patient eligibility for clinical trial enrollment. Measurement of the glomerular filtration rate (GFR) using clearance of exogenous markers provides the most accurate measure of kidney function but is not practical clinically. Although serum creatinine (sCr) level alone has been used to estimate kidney function, it can be influenced by non-GFR physiologic determinants, such as sarcopenia, and nephrology and oncology organization guidelines recommend against using sCr level alone.
1 Several equations incorporating clinical and demographic variables have been developed to improve the estimation of kidney function.
2 Recently, there have been calls for harmonization of most aspects of cancer clinical trial eligibility to foster feasibility, inclusivity, comparability, and generalizability.
3 We sought to understand the landscape of approaches used to estimate kidney function for contemporary cancer clinical trial eligibility.